From Pharmalot, mentions a new Remicade site; also 66 (so far) comments from all viewpoints:
http://www.pharmalot.com/2008/12/is-too-much-safety-information-a-bad-thing/
"Meanwhile, Johnson & Johnson has a new site called Medversation
for its Remicade arthritis drug that contains clinical data written in
plain English about efficacy and detailed explanations of side effects."
Copyright ArthritisInsight.com